Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· October 24, 2025

Byline Bancorp anticipates crossing $10B asset threshold in Q1 2026 while maintaining strong capital and loan growth

View original at seekingalpha.com
Byline Bancorp anticipates crossing $10B asset threshold in Q1 2026 while maintaining strong capital and loan growth Earnings Call Insights: Byline Bancorp, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Company anticipates crossing $10 billion asset threshold during Q1 2026, with Durbin and higher insurance assessments not taking effect until 2027

    80% confidence

  • Deposit outflows in DDA are driven by seasonality

    80% confidence

  • Fixed rate loan maturities for 2026 are roughly $750 million

    80% confidence

  • Commercial payments team focuses on businesses that originate a lot of ACH transactions and process payroll, with impact expected in 2026 and beyond

    80% confidence

  • The margin expanded 9 basis points from last quarter to 4.27%, supported by improved deposit mix and higher asset yields

    80% confidence

  • Noninterest income totaled $15.9 million in Q3, up 9.5% from last quarter, primarily due to $7 million gain on sale of loans driven by higher volumes

    80% confidence

  • During government shutdown, bank cannot sell and settle SBA loans and must hold them on balance sheet until government reopens

    80% confidence

  • Loans grew 6% linked quarter and 11% year-to-date, ending at $7.5 billion; deposits totaled $7.8 billion, up 1% linked quarter and 7% year-to-date

    80% confidence

  • The quarter marked 12 consecutive quarters of very strong financial performance for Byline and highlights the consistency of execution, resiliency of business model and optionality and flexibility in operating model

    80% confidence

  • Profitability metrics for the quarter were once again top quartile and credit quality continues to be stable to improving in some segments despite macroeconomic uncertainty, geopolitical tensions and government shutdown

    80% confidence

  • Durbin Amendment impact estimated at $4.5 million to $5 million annually, not going into effect until July 1 of the year following crossing the threshold

    80% confidence

  • With market expectations of 2 Fed cuts in Q4, net interest income expected to be $97 million to $99 million

    80% confidence

  • Company is actively looking at M&A opportunities while prioritizing funding bank growth and maintaining capital for opportunistic deals

    80% confidence

  • Company is open to disciplined M&A deals that make sense, has capital to be opportunistic and believes it can deliver strong financial results without needing to force a deal

    80% confidence

  • Record net interest income of $99.9 million in Q3, up 4.1% from prior quarter, primarily due to organic loan growth and lower rates paid on deposits

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Byline Bancorp anticipates crossing $10B asset threshold in Q1 2026 while maintaining strong capital and loan growth — Source | Via News | ViaNews Market